Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

被引：1
|
作者：
Delimpasi, Sosana [1 ,2 ]
Dimopoulos, Meletios A. [3 ]
Straub, Jan [4 ]
Symeonidis, Argiris [5 ]
Hajek, Roman [6 ,7 ]
Touzeau, Cyrille [8 ]
Bhanderi, Viralkumar K. [9 ]
Berdeja, Jesus [10 ]
Pavlicek, Petr [11 ]
Matous, Jeffrey, V [12 ,13 ]
Robak, Pawel J. [14 ,15 ]
Suryanarayan, Kaveri [16 ]
Villareal, Miguel [16 ]
Cherepanov, Dasha [1 ,2 ,3 ]
Srimani, Jaydeep K. [16 ]
Yao, Huilan [16 ]
Labotka, Richard [16 ]
Orlowski, Robert Z. [17 ,18 ]
机构：
[1] Gen Hosp Evangelismos, Dept Hematol, Athens, Greece
[2] Gen Hosp Evangelismos, Bone Marrow Transplantat Unit, Athens, Greece
[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece
[4] Univ Hosp, Dept Internal Med Hematol, Prague, Czech Republic
[5] Univ Gen Hosp Patras, Dept Hematol, Patras, Greece
[6] Univ Hosp Ostrava, Ostrava, Czech Republic
[7] Univ Ostrava, Fac Med, Ostrava, Czech Republic
[8] Univ Hosp Hotel Dieu, Nantes, France
[9] Tallahassee Canc Ctr, Florida Canc Specialists, Tallahassee, FL USA
[10] Sarah Cannon Res Inst, Nashville, TN USA
[11] Univ Hosp Kralovske Vinohrady, Dept Internal Med & Hematol, Prague, Czech Republic
[12] Colorado Blood Canc Inst, Denver, CO USA
[13] Sarah Cannon Res Inst, Denver, CO USA
[14] Med Univ Lodz, Dept Hematol, Lodz, Poland
[15] Copernicus Mem Hosp, Lodz, Poland
[16] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[17] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[18] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163092
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9995 / 9997
页数：3
相关论文
共 50 条
  • [21] Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
    Usmani, Saad Zafar
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Grosicki, Sebastian
    Spencer, Andrew
    Bandekar, Rajesh
    Masterson, Tara J.
    Clemens, Pamela L.
    Heuck, Christoph Johann
    Qi, Ming
    Nahi, Hareth
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
    Dimopoulos, Meletios A.
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David S.
    Weisel, Katja
    Gavriatopoulou, Maria
    Oriol, Albert
    Rabin, Neil K.
    Nooka, Ajay
    Qi, Ming
    Ding, Bifeng
    Zahlten-Kumeli, Anita
    Usmani, Saad Z.
    BLOOD, 2020, 136
  • [23] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Safety Run-in Analysis
    Costello, Caitlin L.
    Padilla, Michelle
    Ball, Edward D.
    Mulroney, Carolyn
    BLOOD, 2019, 134
  • [24] Talquetamab (tal) plus Daratumumab (dara) plus Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study
    Bahlis, Nizar J.
    de Donk, Niels van
    Reece, Donna
    Bhutani, Manisha
    Dholaria, Bhagirathbhai
    D'Souza, Anita
    Martin, Thomas
    McKay, John
    Garfall, Alfred
    Krishnan, Amrita
    Bakshi, Kalpana
    Kang, Lijuan
    Vandenberk, Lien
    Prior, Thomas
    Tolbert, Jaszianne
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S1 - S1
  • [25] Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies
    Quach, Hang
    Nooka, Ajay
    Samoylova, Olga
    Venner, Christopher
    Kim, Kihyun
    Facon, Thierry
    Spencer, Andrew
    Usmani, Saad
    Grosicki, Sebastian
    Suzuki, Kenshi
    Delimpasi, Sosana
    Weisel, Katja
    Obreja, Mihaela
    Zahlten-Kumeli, Anita
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S294 - S294
  • [26] FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
    Jakubowiak, A. J.
    Rosenbaum, C. A.
    Stephens, L.
    Kukreti, V.
    Cole, C.
    Zimmerman, T.
    Reece, D.
    Berdeja, J.
    Severson, E.
    Wolfe, B.
    Major, S.
    McDonnell, K.
    Nam, J.
    Turowski, A.
    Griffith, K.
    Zonder, J.
    HAEMATOLOGICA, 2017, 102 : 271 - 271
  • [27] Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study
    Frerichs, Kristine A.
    Minnema, Monique C.
    Levin, Mark-David
    Broyl, Annemiek
    Bos, Gerard
    Kersten, Marie Jose
    Mutis, Tuna
    Verkleij, Christie P. M.
    Bosman, Patricia W. C.
    Klein, Saskia K.
    Zweegman, Sonja
    Sonneveld, Pieter
    Van de Donk, Niels W. C. J.
    BLOOD, 2019, 134
  • [28] EFFICACY AND SAFETY OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: IMPACT OF PRIOR THERAPY IN THE PHASE 3 TOURMALINE-MM1 STUDY
    Mateos, M. V.
    Masszi, T.
    Grzasko, N.
    Hansson, M.
    Sandhu, I.
    Pour, L.
    Viterbo, L.
    Jackson, S.
    Stoppa, A. M.
    Gimsing, P.
    Hamadani, M.
    Borsaru, G.
    Berg, D.
    Lin, J.
    van de Velde, H.
    Richardson, P.
    Moreau, P.
    HAEMATOLOGICA, 2016, 101 : 527 - 527
  • [29] A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM)
    Berenson, James R.
    Klein, Leonard M.
    Rosen, Peter J.
    Woliver, Thomas B. S.
    Eshaghlan, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] PHASE 1 PHARMACOKINETIC (PK) STUDY OF IXAZOMIB CITRATE (MLN9708) PLUS LENALIDOMIDE AND DEXAMETHASONE IN ASIAN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Gupta, N.
    Goh, Y. T.
    Min, C. K.
    Lee, J. H.
    Suh, C.
    Kim, K.
    Wong, R.
    Chim, J.
    Hanley, M. J.
    Yang, H.
    Venkatakrishnan, K.
    Hui, A. M.
    Schusterbauer, C.
    Chng, W. J.
    HAEMATOLOGICA, 2014, 99 : 372 - 372
12345